FDA, FTC to target 'anti-competitive' practices to support biosimilar insulin
Feb 9, 2020 —
The 3 big pharma companies continue to block people with diabetes access to affordable insulin even with new biosimilar drugs. Biosimilar drugs could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines including insulin. Click here to see a short video what a biosimilar drug is. Biosimilar drug manufactures have been touted the many benefits of these drugs including price savings. These statements are true according to the FDA. The big pharma companies including, Eli Lilly (maker of Humalog), Sanofi (maker of Lantus) and Norvo Nordisk (maker of Novolog) has bluntly marketed through videos, websites and social media that biosimilar manufactures are lying about the successes of these drugs.
Because of these ‘anti-competitive statements’ The FDA and the Federal Trade Commission (FTC) on February 3 announced a joint project to crack down on BIG PHARMA "false or misleading" marketing claims about biosimilars, with the implicit aim to boost sales of their drugs they hold everlasting patents on. Biosimilar drugs are gaining popularity in Europe. While Pfizer also creates false claims about biosimilar drugs here in the United States, they are entering the biosimilar market in Europe.
Keep fighting for people power!
Politicians and rich CEOs shouldn't make all the decisions. Today we ask you to help keep Change.org free and independent. Our job as a public benefit company is to help petitions like this one fight back and get heard. If everyone who saw this chipped in monthly we'd secure Change.org's future today. Help us hold the powerful to account. Can you spare a minute to become a member today?I'll power Change with $5 monthly